China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
0.395
+0.005 (1.15%)
Dec 3, 2024, 1:26 PM EST - Market open
China SXT Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2016 |
| Revenue | 1.93 | 1.93 | 1.97 | 2.6 | 4.78 | 5.16 | Upgrade
|
| Revenue Growth (YoY) | -2.19% | -2.19% | -24.23% | -45.53% | -7.45% | -26.38% | Upgrade
|
| Cost of Revenue | 1.37 | 1.37 | 1.55 | 1.35 | 1.94 | 2.46 | Upgrade
|
| Gross Profit | 0.55 | 0.55 | 0.43 | 1.25 | 2.84 | 2.7 | Upgrade
|
| Selling, General & Admin | 2.65 | 2.65 | 5.68 | 6.44 | 5.04 | 4.04 | Upgrade
|
| Operating Expenses | 2.65 | 2.65 | 5.68 | 6.44 | 5.04 | 4.04 | Upgrade
|
| Operating Income | -2.09 | -2.09 | -5.26 | -5.19 | -2.2 | -1.34 | Upgrade
|
| Interest Expense | -0.55 | -0.55 | -0.48 | -0.04 | -1.12 | -3.35 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | - | 0 | 0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.04 | -0.04 | 0.15 | -0.18 | 0.36 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | -2.68 | -2.68 | -5.59 | -5.41 | -2.94 | -4.76 | Upgrade
|
| Asset Writedown | -0.42 | -0.42 | -0.35 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -5.63 | Upgrade
|
| Pretax Income | -3.1 | -3.1 | -5.93 | -5.41 | -2.94 | -10.39 | Upgrade
|
| Income Tax Expense | - | - | - | 0.33 | -0.19 | -0.1 | Upgrade
|
| Net Income | -3.1 | -3.1 | -5.93 | -5.74 | -2.75 | -10.29 | Upgrade
|
| Net Income to Common | -3.1 | -3.1 | -5.93 | -5.74 | -2.75 | -10.29 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 224.91% | 224.91% | 541.90% | 44.50% | 132.79% | 20.23% | Upgrade
|
| EPS (Basic) | -3.57 | -3.57 | -22.23 | -137.92 | -95.48 | -832.08 | Upgrade
|
| EPS (Diluted) | -3.57 | -3.57 | -22.23 | -137.92 | -95.48 | -832.08 | Upgrade
|
| Free Cash Flow | -1.94 | -1.94 | -0.15 | 0.21 | -1.41 | 0.53 | Upgrade
|
| Free Cash Flow Per Share | -2.23 | -2.23 | -0.57 | 4.95 | -48.98 | 42.67 | Upgrade
|
| Gross Margin | 28.73% | 28.73% | 21.62% | 48.10% | 59.43% | 52.37% | Upgrade
|
| Operating Margin | -108.49% | -108.49% | -266.68% | -199.43% | -45.99% | -25.98% | Upgrade
|
| Profit Margin | -160.67% | -160.67% | -301.00% | -220.43% | -57.52% | -199.29% | Upgrade
|
| Free Cash Flow Margin | -100.34% | -100.34% | -7.68% | 7.91% | -29.50% | 10.22% | Upgrade
|
| EBITDA | -1.89 | -1.89 | -5.01 | -4.87 | -1.85 | -1.01 | Upgrade
|
| EBITDA Margin | -97.95% | -97.95% | -253.99% | -187.13% | -38.76% | -19.55% | Upgrade
|
| D&A For EBITDA | 0.2 | 0.2 | 0.25 | 0.32 | 0.35 | 0.33 | Upgrade
|
| EBIT | -2.09 | -2.09 | -5.26 | -5.19 | -2.2 | -1.34 | Upgrade
|
| EBIT Margin | -108.49% | -108.49% | -266.68% | -199.43% | -45.99% | -25.98% | Upgrade
|
| Revenue as Reported | 1.93 | 1.93 | 1.97 | 2.6 | 4.78 | 5.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.